Comparing two ways to give belantamab for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new way to give the drug belantamab as a shot under the skin instead of through an IV, for people who are already on maintenance therapy after a stem cell transplant. It aims to see if the shot works just as well and is more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma and are currently on maintenance therapy with either lenalidomide, an anti-CD38 drug (like daratumumab), or both, after your first or second stem cell transplant.
- Your myeloma treatment hasn't changed in the last 2 months and your disease is at least partially responding.
- Your stem cell transplant was more than 100 days ago, and you are not dependent on blood transfusions or growth factor shots.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You have not had prior treatment with BCMA-targeted therapy (like belantamab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This program provides access to a new drug called belantamab mafodotin, which is being combined with other medicines for people with multiple myeloma who have run out of standard options. The goal is to see if the combination can help control the disease.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.